{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:50:22Z","timestamp":1783342222722,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11096-022-01418-3","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T14:03:32Z","timestamp":1653746612000},"page":"762-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-cardiovascular medication and readmission for heart failure: an observational cohort study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-9027","authenticated-orcid":false,"given":"Willemien J.","family":"Kruik-Koll\u00f6ffel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Vallejo-Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris L. L.","family":"Movig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard C. M.","family":"Linssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M.","family":"Heintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job","family":"van der Palen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"issue":"4","key":"1418_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/circulationaha.112.125435","volume":"126","author":"AS Desai","year":"2012","unstructured":"Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012;126(4):501\u20136. https:\/\/doi.org\/10.1161\/circulationaha.112.125435.","journal-title":"Circulation"},{"issue":"2","key":"1418_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ejhf.1721","volume":"22","author":"PS Jhund","year":"2020","unstructured":"Jhund PS. The recurring problem of heart failure hospitalisations. Eur J Heart Fail. 2020;22(2):249\u201350. https:\/\/doi.org\/10.1002\/ejhf.1721.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"1418_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"1418_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.hlc.2018.06.1042","volume":"27","author":"JJ Atherton","year":"2018","unstructured":"Atherton JJ, Sindone A, Pasquale CGD, et al. National heart foundation of Australia and cardiac society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. 2018;27:1123\u2013208. https:\/\/doi.org\/10.1016\/j.hlc.2018.06.1042.","journal-title":"Heart Lung Circ"},{"key":"1418_CR5","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/cir.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136:e137\u201361. https:\/\/doi.org\/10.1161\/cir.0000000000000509.","journal-title":"Circulation"},{"key":"1418_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC). developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128.","journal-title":"Eur Heart J"},{"issue":"1","key":"1418_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ejhf.30","volume":"16","author":"VM van Deursen","year":"2014","unstructured":"van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European heart failure pilot survey. Eur J Heart Fail. 2014;16(1):103\u201311. https:\/\/doi.org\/10.1002\/ejhf.30.","journal-title":"Eur J Heart Fail"},{"key":"1418_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ejhf.600","volume":"18","author":"F Triposkiadis","year":"2016","unstructured":"Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail. 2016;18:744\u201358. https:\/\/doi.org\/10.1002\/ejhf.600.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1418_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/cir.0000000000000426","volume":"134","author":"RL Page","year":"2016","unstructured":"Page RL, O\u2019Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American heart association. Circulation. 2016;134(6):e32-69. https:\/\/doi.org\/10.1161\/cir.0000000000000426.","journal-title":"Circulation"},{"key":"1418_CR10","unstructured":"PHARMO Database Network: What we have. https:\/\/pharmo.nl\/what-we-have\/pharmo-database-network\/. Accessed 31 Oct 2021"},{"key":"1418_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejca.2009.09.010","volume":"46","author":"MP Van Herk-Sukel","year":"2010","unstructured":"Van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven cancer registry and the PHARMO record linkage system. Eur J Cancer. 2010;46:395\u2013404. https:\/\/doi.org\/10.1016\/j.ejca.2009.09.010.","journal-title":"Eur J Cancer"},{"key":"1418_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ehjcvp\/pvv035","volume":"2","author":"R Kumar","year":"2016","unstructured":"Kumar R, Kerins DM, Walther T. Cardiovascular safety of anti-diabetic drugs. Eur Heart J Cardiovasc Pharmacother. 2016;2:32\u201343. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv035.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1418_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10741-019-09777-2","volume":"24","author":"WJ Kruik-Koll\u00f6ffel","year":"2019","unstructured":"Kruik-Koll\u00f6ffel WJ, Linssen GCM, Kruik HJ, et al. Effects of European society of cardiology guidelines on medication profiles after hospitalisation for heart failure in 22,476 Dutch patients: from 2001 till 2015. Heart Fail Rev. 2019;24:499\u2013510. https:\/\/doi.org\/10.1007\/s10741-019-09777-2.","journal-title":"Heart Fail Rev"},{"key":"1418_CR14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(15)00292-2","volume":"3","author":"A Rosengren","year":"2015","unstructured":"Rosengren A, Vestberg D, Svensson A-M, et al. Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:876\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(15)00292-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1418_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2018;20(5):853\u201372. https:\/\/doi.org\/10.1002\/ejhf.1170.","journal-title":"Eur J Heart Fail"},{"key":"1418_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","volume":"385","author":"RE Gilbert","year":"2015","unstructured":"Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385:2107\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(14)61402-1.","journal-title":"Lancet"},{"key":"1418_CR17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ejhf.1146","volume":"20","author":"F Cosmi","year":"2018","unstructured":"Cosmi F, Shen L, Magnoli M, et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. 2018;20:888\u201395. https:\/\/doi.org\/10.1002\/ejhf.1146.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1418_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"1418_CR19","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. Last updated Dec 2020, 16. Available from https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/Recommendations#drug-treatment-2. Accessed 31 Oct 2021"},{"key":"1418_CR20","unstructured":"Barents ESE, Bilo HJG, Bouma M, et al. Diabetes mellitus type 2. NHG, Dutch College of General Practitioners. September 2018. https:\/\/richtlijnen.nhg.org\/standaarden\/diabetes-mellitus-type-2. Accessed 31 Oct 2021"},{"key":"1418_CR21","first-page":"616","volume":"14","author":"K Azimova","year":"2014","unstructured":"Azimova K, Juan ZS, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014;14:616\u201332.","journal-title":"Ochsner J"},{"key":"1418_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/00325481.2017.1358064","volume":"129","author":"S Yandrapalli","year":"2017","unstructured":"Yandrapalli S, Jolly G, Horblitt A, et al. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgrad Med. 2017;129:811\u201321. https:\/\/doi.org\/10.1080\/00325481.2017.1358064.","journal-title":"Postgrad Med"},{"key":"1418_CR23","doi-asserted-by":"publisher","first-page":"i3477","DOI":"10.1136\/bmj.i3477","volume":"354","author":"J Hippisley-Cox","year":"2016","unstructured":"Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016;354:i3477. https:\/\/doi.org\/10.1136\/bmj.i3477.","journal-title":"BMJ"},{"issue":"2","key":"1418_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ejhf.1673","volume":"22","author":"PM Seferovi\u0107","year":"2020","unstructured":"Seferovi\u0107 PM, Coats AJS, Ponikowski P, et al. European society of cardiology\/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020;22(2):196\u2013213. https:\/\/doi.org\/10.1002\/ejhf.1673.","journal-title":"Eur J Heart Fail"},{"key":"1418_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/2042098617690485","volume":"8","author":"A Fanelli","year":"2017","unstructured":"Fanelli A, Ghisi D, Aprile PL, et al. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf. 2017;8:173\u201382.","journal-title":"Ther Adv Drug Saf"},{"issue":"13","key":"1418_CR26","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/eurheartj\/ehv505","volume":"37","author":"M Schmidt","year":"2016","unstructured":"Schmidt M, Lamberts M, Schjerning Olsen A, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for cardiovascular pharmacotherapy of the European society of cardiology. Eur Heart J. 2016;37(13):1015\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehv505.","journal-title":"Eur Heart J"},{"key":"1418_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","volume":"16","author":"H Huang","year":"2014","unstructured":"Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16:15\u201324. https:\/\/doi.org\/10.1093\/eurjhf\/hft132.","journal-title":"Eur J Heart Fail"},{"issue":"2_Suppl","key":"1418_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/2047487320957793","volume":"27","author":"A Tedeschi","year":"2020","unstructured":"Tedeschi A, Agostoni P, Pezzuto B, et al. Role of comorbidities in heart failure prognosis part 2: chronic kidney disease, elevated serum uric acid. Eur J Prev Cardiol. 2020;27(2_Suppl):35\u201345. https:\/\/doi.org\/10.1177\/2047487320957793.","journal-title":"Eur J Prev Cardiol"},{"key":"1418_CR29","doi-asserted-by":"publisher","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout Lancet. 2016;388(10055):2039\u20132052. https:\/\/doi.org\/10.1016\/S0140-6736(16)00346-9","DOI":"10.1016\/S0140-6736(16)00346-9"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01418-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01418-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01418-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T14:27:57Z","timestamp":1655303277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01418-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01418-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"31 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Parallel to this research at Medisch Spectrum Twente (MST), Enschede, the Netherlands, the author Enriqueta Vallejo-Yag\u00fce worked at Synovo GmbH (T\u00fcbingen, Germany, pharmaceutical biotech company engaged in discovery and drug development). Conflicts of interest for the other authors: none declared.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}